|
PELO expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.80917000000003E-05 |
| Normal-vs-Stage3 |
9.44799793956008E-14 |
| Normal-vs-Stage4 |
1.71795910830497E-12 |
| Stage1-vs-Stage2 |
2.678000E-01 |
| Stage1-vs-Stage3 |
7.557600E-01 |
| Stage1-vs-Stage4 |
3.711700E-02 |
| Stage2-vs-Stage3 |
2.301400E-01 |
| Stage2-vs-Stage4 |
2.479600E-02 |
| Stage3-vs-Stage4 |
1.017420E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
7.71993580173103E-12 |
| Normal-vs-Asian |
7.96769983324452E-10 |
| Caucasian-vs-AfricanAmerican |
5.648600E-01 |
| Caucasian-vs-Asian |
5.715600E-01 |
| AfricanAmerican-vs-Asian |
3.337800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.35935707135104E-12 |
| Normal-vs-Female |
1.62481139653892E-12 |
| Male-vs-Female |
3.497600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.55431223447522E-14 |
| Normal-vs-Age(61-80Yrs) |
3.30246940904999E-12 |
| Normal-vs-Age(81-100Yrs) |
4.383600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.941600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.145000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.848600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.593400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.729640E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.318190E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.682300E-02 |
| Classical-VS-Follicular |
3.590600E-01 |
| Classical-VS-Other |
4.417400E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
3.614200E-01 |
| Tall-VS-Other |
8.013400E-01 |
| Tall-VS-Normal |
3.51063622616721E-12 |
| Follicular-VS-Other |
5.047400E-01 |
| Follicular-VS-Normal |
1.45059964040684E-10 |
| Other-VS-Normal |
1.750810E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.50990331349021E-14 |
| Normal-vs-N1 |
1.85740312019789E-13 |
| N0-vs-N1 |
2.340000E-02 |
|
|
